Paper30728151
Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer.
Pfannenstiel LW and 5 others. Cancer Immunol Res, 2019. Cited by 43 papers, by iCite.
Cite this record
ConductScience Library. Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer. Papers, record 30728151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30728151
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CD8-Positive T-Lymphocytes | Major topic |
| Hepatitis A Virus Cellular Receptor 2 | Major topic |
| Lymphocytes, Tumor-Infiltrating | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Animals | |
| Antibodies, Blocking | |
| Cell Proliferation | |
| Disease Models, Animal | |
| Head and Neck Neoplasms | |
| Humans | |
| Immunotherapy | |
| Interleukin-10 | |
| Interleukin-7 | |
| Ligands | |
| Mice | |
| Squamous Cell Carcinoma of Head and Neck | |
| Tumor Microenvironment |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA132796 | NCI NIH HHS | United States | R01CA132796 | PubMed and NIH |
Source NIH RePORTER
References55
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21430066 | Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. | Cancer Res | 2011 | https://conductscience.org/library/papers/21430066 | PubMed |
| 2 | 17878327 | CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. | J Immunol | 2007 | https://conductscience.org/library/papers/17878327 | PubMed |
| 3 | 18245489 | Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. | Cancer Res | 2008 | https://conductscience.org/library/papers/18245489 | PubMed |
| 4 | 20525992 | Improved survival with ipilimumab in patients with metastatic melanoma. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20525992 | PubMed |
| 5 | 25559415 | Cancer statistics, 2015. | CA Cancer J Clin | 2015 | https://conductscience.org/library/papers/25559415 | PubMed |
| 6 | 28331612 | Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. | Biomark Res | 2017 | https://conductscience.org/library/papers/28331612 | PubMed |
| 7 | 25695955 | PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. | Mol Cancer Ther | 2015 | https://conductscience.org/library/papers/25695955 | PubMed |
| 8 | 26965076 | Vaccines for established cancer: overcoming the challenges posed by immune evasion. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/26965076 | PubMed |
| 9 | 23633484 | Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. | Cancer Res | 2013 | https://conductscience.org/library/papers/23633484 | PubMed |
| 10 | 29163783 | Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. | Oncotarget | 2017 | https://conductscience.org/library/papers/29163783 | PubMed |
| 11 | 22437870 | The blockade of immune checkpoints in cancer immunotherapy. | Nat Rev Cancer | 2012 | https://conductscience.org/library/papers/22437870 | PubMed |
| 12 | 16946036 | Cancer regression in patients after transfer of genetically engineered lymphocytes. | Science | 2006 | https://conductscience.org/library/papers/16946036 | PubMed |
| 13 | 25624094 | Immunotherapy for head and neck squamous cell carcinoma. | Oral Oncol | 2015 | https://conductscience.org/library/papers/25624094 | PubMed |
| 14 | 21385853 | Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. | Blood | 2011 | https://conductscience.org/library/papers/21385853 | PubMed |
| 15 | 22581824 | IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. | Cancer Res | 2012 | https://conductscience.org/library/papers/22581824 | PubMed |
| 16 | 22592956 | Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22592956 | PubMed |
| 17 | 19423728 | Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. | Blood | 2009 | https://conductscience.org/library/papers/19423728 | PubMed |
| 18 | 18006747 | Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. | Science | 2007 | https://conductscience.org/library/papers/18006747 | PubMed |
| 19 | 25823918 | The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. | Clin Ther | 2015 | https://conductscience.org/library/papers/25823918 | PubMed |
| 20 | 22658127 | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22658127 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41961948 | Single-cell TCR mapping reveals spatially coordinated T cell states in head and neck cancer. | Sci Immunol | 2026 | https://conductscience.org/library/papers/41961948 | PubMed |
| 39025962 | T cell dysfunction and therapeutic intervention in cancer. | Nat Immunol | 2024 | https://conductscience.org/library/papers/39025962 | PubMed |
| 38296598 | Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity. | J Immunother Cancer | 2024 | https://conductscience.org/library/papers/38296598 | PubMed |
| 38023136 | A transcriptional evaluation of the melanoma and squamous cell carcinoma TIL compartment reveals an unexpected spectrum of exhausted and functional T cells. | Front Oncol | 2023 | https://conductscience.org/library/papers/38023136 | PubMed |
| 36543958 | Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. | Nat Immunol | 2023 | https://conductscience.org/library/papers/36543958 | PubMed |
| 35954318 | Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35954318 | PubMed |
| 35534320 | A hitchhiker's guide to cancer models. | Trends Biotechnol | 2022 | https://conductscience.org/library/papers/35534320 | PubMed |
| 35292828 | Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer. | Cancer Immunol Immunother | 2022 | https://conductscience.org/library/papers/35292828 | PubMed |
| 35159220 | Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. | Cells | 2022 | https://conductscience.org/library/papers/35159220 | PubMed |
| 34925340 | EZH2 Inhibition Compromises α4-1BB-Mediated Antitumor Efficacy by Reducing the Survival and Effector Programming of CD8+ T Cells. | Front Immunol | 2021 | https://conductscience.org/library/papers/34925340 | PubMed |
| 34900690 | Alphataxin, a Small-Molecule Drug That Elevates Tumor-Infiltrating CD4+ T Cells, in Combination With Anti-PD-1 Therapy, Suppresses Murine Renal Cancer and Metastasis. | Front Oncol | 2021 | https://conductscience.org/library/papers/34900690 | PubMed |
| 34807232 | A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. | J Exp Med | 2022 | https://conductscience.org/library/papers/34807232 | PubMed |
| 34208113 | Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34208113 | PubMed |
| 33924671 | Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients. | J Pers Med | 2021 | https://conductscience.org/library/papers/33924671 | PubMed |
| 33802622 | Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C. | Cells | 2021 | https://conductscience.org/library/papers/33802622 | PubMed |
| 33762351 | Chronic Adrenergic Stress Contributes to Metabolic Dysfunction and an Exhausted Phenotype in T Cells in the Tumor Microenvironment. | Cancer Immunol Res | 2021 | https://conductscience.org/library/papers/33762351 | PubMed |
| 33654395 | Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors. | Int J Nanomedicine | 2021 | https://conductscience.org/library/papers/33654395 | PubMed |
| 33627484 | Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. | Sci Transl Med | 2021 | https://conductscience.org/library/papers/33627484 | PubMed |
| 33559853 | Interleukin (IL)-7 Signaling in the Tumor Microenvironment. | Adv Exp Med Biol | 2021 | https://conductscience.org/library/papers/33559853 | PubMed |
| 33262762 | Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. | Front Immunol | 2020 | https://conductscience.org/library/papers/33262762 | PubMed |
Genes19
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30728151
GET https://conductscience.org/api/papers/v1/30728151/references?page=2